Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Aug 04, 2022 7:31am
154 Views
Post# 34870400

RE:Interesting at least

RE:Interesting at least
Thanks for posting this.

I doubt this reflects any meaningful changes in GUD's potential. I doubt much changed within the past month. The only clear change, in fact, was the stock price, which creeped up a little bit. I'd bet a lot of money this has to do with this particular investor's style of investing.

My opinion of GUD, at least, didn't change a little over a month ago when he invested nor does it change when he sells.

The story remains the same:

+ as of right now, we grow at a good rate (profitably!) within our current portfolio,
+ as opportunities arise, we in-license and acquire,
+ in the meantime, we allocate the capital intelligently, which currently means buying back our stock.

I see no reason to think the story has changed, and the valuation remains roughly the same as it's been for a long time. :)
<< Previous
Bullboard Posts
Next >>